Royalty Pharma announces a $0.22 quarterly dividend for Class A shares, payable December 10, 2025, to eligible shareholders.
Quiver AI Summary
Royalty Pharma plc has announced a fourth-quarter dividend of $0.22 per Class A ordinary share, which will be paid on December 10, 2025, to shareholders recorded by November 14, 2025. Established in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and actively funds innovation in the biopharmaceutical sector through partnerships and acquisitions. The company has a diverse portfolio that includes royalties from over 35 commercial products, such as Trikafta, Tremfya, and Evrysdi, along with 17 development-stage candidates. For more details, investors can visit their website or contact their investor relations team.
Potential Positives
- The approval of a dividend payment reflects the company's financial stability and commitment to returning value to its shareholders.
- Royalty Pharma's diverse portfolio of more than 35 commercial products and development-stage candidates highlights its strong position in the biopharmaceutical industry.
- The company's role as a leader in funding innovation in the biopharmaceutical sector underscores its importance in advancing healthcare solutions.
Potential Negatives
- Dividend payment may indicate limited growth opportunities if the company is prioritizing returns to shareholders over reinvesting profits into expansion or innovation.
- Approval of a $0.22 dividend could raise concerns among investors regarding the overall profitability and financial health of the company if perceived as a response to weaker-than-expected earnings.
FAQ
What is the dividend amount announced by Royalty Pharma for Q4 2025?
The board approved a dividend of $0.22 per Class A ordinary share for the fourth quarter of 2025.
When will Royalty Pharma pay the Q4 2025 dividend?
The dividend will be paid on December 10, 2025, to shareholders of record as of November 14, 2025.
How does Royalty Pharma support biopharmaceutical innovation?
Royalty Pharma funds biopharmaceutical innovation by co-funding trials and acquiring existing royalties from innovators.
Which companies' products are included in Royalty Pharma's portfolio?
The portfolio includes commercial products from Vertex, Johnson & Johnson, GSK, Roche, and many more.
What is the focus of Royalty Pharma's business model?
Royalty Pharma focuses on buying biopharmaceutical royalties and funding innovation across the biopharmaceutical industry.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- GREGORY NORDEN sold 33,500 shares for an estimated $1,213,748
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPRX Hedge Fund Activity
We have seen 245 institutional investors add shares of $RPRX stock to their portfolio, and 212 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 21,880,620 shares (+inf%) to their portfolio in Q2 2025, for an estimated $788,358,738
- VIKING GLOBAL INVESTORS LP removed 7,966,479 shares (-75.4%) from their portfolio in Q2 2025, for an estimated $287,032,238
- MORGAN STANLEY added 5,574,271 shares (+13.6%) to their portfolio in Q2 2025, for an estimated $200,840,984
- BAILLIE GIFFORD & CO added 4,618,171 shares (+34.5%) to their portfolio in Q2 2025, for an estimated $166,392,701
- GMT CAPITAL CORP removed 2,377,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $85,661,325
- TWO SIGMA ADVISERS, LP removed 2,057,000 shares (-70.8%) from their portfolio in Q2 2025, for an estimated $74,113,710
- BANK OF AMERICA CORP /DE/ removed 1,984,239 shares (-49.3%) from their portfolio in Q2 2025, for an estimated $71,492,131
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- Goldman Sachs issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 3 analysts offer price targets for $RPRX in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $54.0 on 10/10/2025
- Asad Haider from Goldman Sachs set a target price of $42.0 on 09/30/2025
- Geoff Meacham from Citigroup set a target price of $42.0 on 07/22/2025
Full Release
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.
The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com. For more information, visit www.royaltypharma.com .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
[email protected]
